$PYXS News
Last published 1d ago
- 1d agoPYXSSTIFEL 2026 HEALTHCARE CONFERENCE - PYXIS ONCOLOGY INCEarnings Call TranscriptsI'm Stephen Woolley, one of the senior biotech analysts here at Stifel, and glad to have with us to wrap up day one of this Stifle Healthcare Conference, Tom Sivick, CEO of Pixis. Tom, thanks for joining us, and not sure
- 2d agoPYXSGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PYXIS ONCOLOGY INCEarnings Call TranscriptsAll right, so welcome to this next Fireside Chat. My name is Michael Schmidt, and I'm pleased to welcome the Pixis team with us today. We have Tom Civic, CEO. Tom, welcome. Thanks for joining us. Thank you for having us.
- 6d agoPYXSPyxis Oncology, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02
- 6d agoPYXSPyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)GlobeNewswireUpdated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) showed compelling efficacy data with a manageable safety profile FDA feedback on
- 2w agoPYXSPyxis Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief
- 2w agoPYXSPyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewswireBOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral
- 2mo agoPYXSPyxis Oncology MICVO Monotherapy Ph1 Clinical Update - PYXIS ONCOLOGY INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to PIXUS Oncology McVoe Monotherapy Phase 1 Clinical Update. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will
- 2mo agoPYXSPyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)GlobeNewswireMICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups
- 2mo agoPYXSPyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)GlobeNewswireBOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live
- 2mo agoPYXSPyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the BoardGlobeNewswireJohn Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board Leadership transition reflects continued focus on advancing MICVO through key clinical milestones BOSTON, Sept. 08,
- 2mo agoPYXSPyxis Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim
- 3mo agoPYXSPyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical MilestonesGlobeNewswireUpdated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO
- 4mo agoPYXSPyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical MilestonesGlobeNewswireExpected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase 1 monotherapy data
- 5mo agoPYXSJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - PYXIS ONCOLOGY INCEarnings Call TranscriptsGood morning, everyone. My name is Farzin Haque, one of the biotech analysts at Jefferies. It's my pleasure to introduce Tom Civic, CEO of Pixus Oncology. This is a fireside chat format. Thank you for joining us today, T
- 5mo agoPYXS2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM - PYXIS ONCOLOGY INCEarnings Call TranscriptsAll right. Good afternoon, everyone. I'm Steve Willie, one of the senior biotech analysts here at Stifel, and glad to have with us from Pixis Oncology, interim CEO, Tom Civic. Tom, thanks for joining us here this afterno
- 6mo agoPYXSPyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical MilestonesGlobeNewswireUpdated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients
- 6mo agoPYXSPyxis Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will
- 6mo agoPYXSPyxis Oncology Appoints Nelson Azoulay as Chief Business OfficerGlobeNewswireBOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson
- 6mo agoPYXSPyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026GlobeNewswireMouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in a syngeneic
- 7mo agoPYXSPyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireCompleted target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated
- 9mo agoPYXSPyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program ContinuityGlobeNewswireBOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to
- 10mo agoALLOCHRSELVNONCY+1The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent CliffGlobeNewswireVANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming
- 10mo agoPYXSPyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaGlobeNewswire46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with
- 1y agoPYXSPyxis Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will
- 1y agoPYXSPyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswire- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of
- 1y agoPYXSPyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical MeetingsGlobeNewswireTranslational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing,
- 1y agoPYXSPyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital MarketsGlobeNewswireBOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the
- 1y agoPYXSPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC') therapeutics for difficult-to-treat cancers, reported
- 1y agoPYXSPyxis Oncology to Participate in September Investor and Industry ConferencesGlobeNewswireBOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S.
- 1y agoPYXSPyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of
- 1y agoPYXSPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC') therapeutics for difficult-to-treat cancers, reported
- 1y agoPYXSPyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and
- 1y agoPYXSPyxis Oncology to Participate in Two Upcoming Investor ConferencesGlobeNewswireBOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan,
- 1y agoPYXSPyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADCGlobeNewswireGene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse
- 1y agoPYXSPyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology ForumGlobeNewswireBOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan,
- 1y agoPYXSPyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025GlobeNewswireExpression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response
- 1y agoPYXSPyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and
- 1y agoPYXSPyxis Oncology to Participate at the Leerink Partners Global Healthcare ConferenceGlobeNewswireBOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan,
- 1y agoPYXSPyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck CancerGlobeNewswireBOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug
- 1y agoPYXSPyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy TrialGlobeNewswire- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck's KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 monotherapy trial
- 1y agoPYXSPyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201GlobeNewswire- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell
- 1y agoPYXSPyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 DataGlobeNewswire— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy
- 1y agoPYXSPyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024GlobeNewswire- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET -
- 2y agoPYXSPyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201GlobeNewswireBOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that it
- 2y agoPYXSPyxis Oncology to Participate in Two Upcoming Investor ConferencesGlobeNewswireBOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara
- 2y agoPYXSPyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024GlobeNewswire- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash
- 2y agoPYXSPyxis Oncology to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewswireBOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara
- 2y agoPYXSPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis
- 2y agoPYXSSNDXPyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerGlobeNewswireBOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the
- 2y agoPYXSPyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara